Get the Stockscreener App
9.96
2.06%
-0.21
Pre-market:
9.96
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $9.96, with a volume of 12.17M.
It is down -2.06% in the last 24 hours and down -1.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.17
Open:
$10.09
24h Volume:
12.17M
Relative Volume:
1.28
Market Cap:
$11.61B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.142
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-5.14%
1M Performance:
-1.58%
6M Performance:
+7.79%
1Y Performance:
-15.23%
1-Day Range:
$9.94
$10.19
1-Week Range:
$9.94
$10.55
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.96 | 11.94B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris chief commercial officer Le Goff sells $72k in stock - Investing.com Nigeria
Real time scanner hits for Viatris Inc. explainedMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Viatris Investors Face Skeptical Judges on Biosimilars Unit (1) - Bloomberg Law News
US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche - Yahoo Finance
Viatris receives FDA warning letter for 11 drugs made at India plant - MSN
Trend analysis for Viatris Inc. this weekTreasury Yields & Stepwise Trade Signal Guides - Newser
Is Viatris Inc. Starting a New UptrendEarnings Summary Report & Reliable Momentum Entry Alerts - beatles.ru
Viatris Inc. Forms Double Bottom Pattern — Eyes on Breakout2025 Market WrapUp & Fast Moving Market Watchlists - beatles.ru
What makes Viatris Inc. stock attractive to long term investorsQuarterly Trade Report & AI Forecasted Stock Moves - beatles.ru
Is Viatris Inc. reversing from oversold territoryPortfolio Performance Summary & Consistent Growth Equity Picks - Newser
Custom strategy builders for tracking Viatris Inc.July 2025 Summary & Free Long-Term Investment Growth Plans - Newser
Stock Analysis | Viatris OutlookA Technical Bear Market with Mixed Fundamentals - AInvest
Candlestick signals on Viatris Inc. stock todayJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - Newser
How volatile is Viatris Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - خودرو بانک
Will a bounce in Viatris Inc. offer an exitJuly 2025 Short Interest & Weekly Top Performers Watchlists - Newser
When is the best time to exit Viatris Inc.Weekly Stock Analysis & Verified Chart Pattern Signals - Newser
Generic Drugs Market is expected to reach US$ 942.69 billion - openPR.com
How to escape a deep drawdown in Viatris Inc.Earnings Risk Summary & Smart Swing Trading Alerts - Newser
What high frequency data says about Viatris Inc.2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
How to use a screener to detect Viatris Inc. breakoutsVolume Spike & Expert Curated Trade Setups - Newser
Fda discontinues manufacture of Dymista, nasal spray, 137 ug 50 ug - MarketScreener
How to use Fibonacci retracement on Viatris Inc.2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris - sharewise.com
Using economic indicators to assess Viatris Inc. potential2025 Risk Factors & Expert Curated Trade Setups - Newser
Risk adjusted return profile for Viatris Inc. analyzedGold Moves & Verified Momentum Stock Alerts - Newser
How moving averages guide Viatris Inc. trading2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Using fundamentals and technicals on Viatris Inc.Earnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
Evaluating Viatris Inc. with trendline analysisEarnings Performance Report & Safe Capital Growth Trade Ideas - Newser
Statistical indicators supporting Viatris Inc.’s strengthStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
Can machine learning forecast Viatris Inc. recovery2025 Top Decliners & Fast Gain Swing Trade Alerts - Newser
Using data tools to time your Viatris Inc. exitJuly 2025 Outlook & AI Powered Trade Plan Recommendations - Newser
Can Viatris Inc. recover in the next quarterCPI Data & Expert Approved Momentum Ideas - Newser
Is Viatris Inc. a cyclical or defensive stockJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - خودرو بانک
What are the risks of holding Viatris Inc.Weekly Risk Summary & Low Volatility Stock Suggestions - خودرو بانک
Is Viatris Inc. stock a top performer YTDQuarterly Risk Review & Fast Exit and Entry Trade Guides - خودرو بانک
Can Viatris Inc. deliver consistent EPS growthJuly 2025 Review & Stepwise Trade Signal Guides - خودرو بانک
Can Viatris Inc. navigate macro headwindsQuarterly Investment Review & Free Daily Entry Point Trade Alerts - خودرو بانک
Analyzing recovery setups for Viatris Inc. investorsMarket Performance Report & Advanced Technical Signal Analysis - Newser
Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider - GlobeNewswire Inc.
Did Viatris’ (VTRS) Executive Reshuffle Centralize Transformation or Signal a Deeper Strategic Shift? - simplywall.st
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):